Document:

Exhibit

Exhibit 10.1
	
		
	
	Tableau Software, Inc.
837 North 34th Street, Suite 400
Seattle, Washington 98103
Phone:  (206) 633-3400
Fax:  (206) 633-3004

August 8,  2016

Dear Adam:
Tableau Software, Inc. (the “Company”) is pleased to offer you employment as the Company’s President and Chief Executive Officer on the terms and conditions set forth in this letter agreement (the “Agreement”).  
1.Position:  Your title will be President and Chief Executive Officer, reporting to the Company’s Board of Directors (the “Board”).  This is a full-time position based out of the Company’s headquarters in Seattle, Washington.  In connection with your appointment as President and Chief Executive Officer, it is anticipated that you will also be appointed as a member of the Board.  While you are employed at the Company, you will abide by your duty of loyalty and duty of care to the Company, perform your duties and follow the lawful directions of the Board in a diligent manner, and devote your full time, energy and attention to the interests of the Company. By signing this Agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company.  Your employment with the Company will start on or before September 16, 2016 (the “Start Date”).  
2.Cash Compensation.  
(a)    Salary.  The Company will pay you a salary of $500,000 per year, less applicable deductions and withholdings, to be paid each month in accordance with the Company’s payroll practices, as may be in effect from time to time.   This salary will be subject to adjustment pursuant to the Company’s annual executive performance assessment and compensation policies in effect from time to time. 
(b)    Performance Bonuses.  Each calendar year, you will be eligible to earn an annual incentive bonus in an amount up to 100% of your annual base salary.  Whether you receive such a bonus, and the amount of any such bonus, shall be determined by the Compensation Committee of the Board in its sole discretion, and shall be based upon achievement of performance objectives to be mutually agreed upon between you and the Compensation Committee and any other criteria to be determined by the Compensation Committee.  Any bonus shall be paid in accordance with the Company’s standard executive performance assessment schedule, only after the Compensation Committee’s determination that a bonus shall be awarded.  For calendar year 2016, the full prorated amount of the annual incentive bonus (calculated from your Start Date through December 31, 2016, less deductions and withholdings) will be paid to you on or before February 28, 2017.   If, after a full calendar year but prior to payment of any such annual incentive bonus, your employment is terminated without Cause, the full amount of the annual incentive bonus, less deduction and withholdings, will be paid to you.  Unless otherwise provided herein, you must be employed on the day that your bonus (if any) is paid in order to earn the bonus.  
(c)    Signing Bonus.  Subject to you starting work on or before September 16, 2016, the Company will pay you a lump sum cash signing bonus of $1,000,000, subject to applicable deductions and withholdings.   The signing bonus will be paid on or before the 30th day following your Start Date, however, the full amount will not be deemed earned until you complete two 

1

	
		
	
	Tableau Software, Inc.
837 North 34th Street, Suite 400
Seattle, Washington 98103
Phone:  (206) 633-3400
Fax:  (206) 633-3004

years of employment.  If you are terminated for Cause or you resign without Good Reason, in either case within the first eighteen months of your employment, then you will be required to repay $500,000 of the signing bonus within thirty days after your final day of employment.  If you are terminated for Cause or you resign without Good Reason, in either case within months nineteen through twenty-four of your employment, then you will be required to repay $250,000 of the signing bonus within thirty days after your final day of employment.

3.Equity. The Company shall, subject to the final approval of the Compensation Committee and the commencement of your employment, grant you:
(a) RSUs.  Restricted stock units (“RSUs”) covering a number of shares of the Company’s Class A Common Stock equal to (x) $14.0 million divided by (y) the trailing average closing sales price of the Company’s Class A Common Stock from August 15, 2016 through September 15, 2016, the last trading day preceding the date of grant, which shall be your Start Date, rounding up to the nearest whole share.  The Vesting Commencement Date for the RSUs Grant will be your Start Date.    
(b)  Options.  An option to purchase 75,000 shares of the Company’s Class A Common Stock (the “Options”).  The Options shall have an exercise price equal to 100% of the fair market value of the Company’s common stock on the date of grant, which shall be your Start Date. The Vesting Commencement Date for the Options will be your Start Date.    
Twenty-five percent (25%) of the RSUs and the Options under the Initial Hire Grant will vest on August 15, 2017, and the remainder will vest quarterly over the three following years, so long as you remain in the Continuous Service of the Company (as defined in the Company’s 2013 Equity Incentive Plan), subject to acceleration as set forth in your Change in Control Severance Agreement with the Company and in Section 5(b) of this Agreement. 
The RSUs and the Options in this Section 3 are collectively referred to herein as the “Initial Hire Grant”) and shall be made pursuant to the terms and conditions of the Company’s standard form RSU Grant Notice and Agreement and Stock Option Grant Notice and Agreement previously approved for use by the Board under the company’s 2013 Equity Incentive Plan (the “Plan”).  
After this Initial Hire Grant, you will eligible for additional equity awards in connection with the Compensation Committee’s annual review of executive compensation. The first such annual review process will commence one-year after your Start Date.  
4.Benefits.  You will be eligible to participate in the Company’s standard benefit programs, subject to the terms and conditions of such plans.  The Company may, from time to time, change these benefits in its discretion.  Additional information regarding these benefits is available for your review upon request.  

2

	
		
	
	Tableau Software, Inc.
837 North 34th Street, Suite 400
Seattle, Washington 98103
Phone:  (206) 633-3400
Fax:  (206) 633-3004

5.Severance.
(a)    Termination for Cause.  If, at any time, the Company terminates your employment for Cause (as defined herein), you will receive your base salary accrued through your last day of employment, as well as any unused vacation (if applicable) accrued through your last day of employment.  Under these circumstances, you will not be entitled to any other form of compensation from the Company, including any severance benefits.
(b)    Termination without Cause.  If, within the four year period following the Start Date, the Company terminates your employment without Cause (as defined herein), or you resign for Good Reason (not in the context of a Change of Control, but as otherwise defined in paragraph 6(g) of your Change in Control Severance Agreement) or  as a result of your death or disability (with timing and other modifications necessary to satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A and related regulations), and provided such termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a “Separation from Service”), then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the “Severance Benefits”):
(i)    an amount equal to 18 months of your then-current base salary, less all applicable withholdings and deductions, paid over such 18 month period on the schedule described below (the “Salary Continuation”);  
(ii)    a lump-sum cash payment equal to your target bonus for the calendar year in which your Separation from Service occurs, prorated based on the percentage of the calendar year that you were employed by the Company, less deductions and withholdings, paid at the same time as the first Salary Continuation payment set forth in subsection (i) above;
(iii)    if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Company’s group health plans following such termination, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A) the close of the 18 month period following the termination of your employment, (B) the expiration of your eligibility for the continuation coverage under COBRA, or (C) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A) through (C), the “COBRA Payment Period”). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the payment of the COBRA premiums could result in a violation of applicable law, then in lieu of providing the COBRA premiums, the Company, in its sole discretion, may elect to instead pay you on the first day of each month of the COBRA Payment Period, a fully taxable cash payment equal to the COBRA premiums for that month, subject to applicable tax withholdings, for the remainder of the COBRA Payment Period, which you may, but are not obligated to, use toward the cost of COBRA premiums.  If you become eligible for substantially equivalent coverage under another employer's group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause shall cease; and

3

	
		
	
	Tableau Software, Inc.
837 North 34th Street, Suite 400
Seattle, Washington 98103
Phone:  (206) 633-3400
Fax:  (206) 633-3004

(iv)    The Company will accelerate the vesting of all then-unvested Company equity awards you hold such that, as of the date of termination, you will be deemed to have vested in those awards as if you had been in service for an additional 12 months following your termination date (based upon months of service and not the occurrence of corporate events or milestones).
Such Severance Benefits are conditional upon (a) your continuing to comply with your obligations under your Confidential Information and Inventions Assignment Agreement; (b) your delivering to the Company an effective, general release of claims in favor of the Company in a form acceptable to the Company within 60 days following your termination date; and (c) if you are a member of the Board, your resignation from the Board, to be effective no later than the date of your termination date (or such other date as requested by the Board).  The Salary Continuation will be paid in equal installments on the Company’s regular payroll schedule and will be subject to applicable tax withholdings over the period outlined above following the date of your termination date; provided, however, that no payments will be made prior to the 60th day following your Separation from Service.  On the 60th day following your Separation from Service, the Company will pay you in a lump sum the Salary Continuation that you would have received on or prior to such date under the original schedule but for the delay while waiting for the 60th day in compliance with Code Section 409A and the effectiveness of the release, with the balance of the Salary Continuation being paid as originally scheduled.  
For sake of clarity, you shall not be eligible for severance benefits under this Section 5(b) if your termination constitutes a Covered Termination under your Change in Control Severance Agreement (as described in Section 5(d) below).
(c)    Definition of Cause.  For purposes of this Agreement, “Cause” shall mean one or more of the following:  (i) your willful failure substantially to perform your duties and responsibilities to the Company or deliberate and material violation of a Company policy; (ii) your commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury to the Company; (iii) your unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company; or (iv) your willful and material breach of any of your obligations under any written agreement or covenant with the Company.  The determination as to whether you are being terminated for Cause shall be made in good faith by the Company.  The foregoing definition does not in any way limit the Company’s ability to terminate your employment at any time.
(d)    Change in Control Severance Agreement.  You will also be eligible for severance benefits under the Company’s standard executive form of Change in Control Severance Agreement.
6.Section 409A.  It is intended that all of the severance benefits and other payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A‐1(b)(4), 1.409A‐1(b)(5) and 1.409A‐1(b)(9), and this Agreement will be construed to the greatest extent possible as consistent with those provisions.  For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A‐2(b)(2)(iii)), your right to receive any installment payments under this letter (whether severance payments, reimbursements or otherwise) 

4

	
		
	
	Tableau Software, Inc.
837 North 34th Street, Suite 400
Seattle, Washington 98103
Phone:  (206) 633-3400
Fax:  (206) 633-3004

shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment.  Notwithstanding any provision to the contrary in this Agreement, if you are deemed by the Company at the time of your Separation from Service to be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be “deferred compensation”, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall not be provided to you prior to the earliest of (i) the expiration of the six-month period measured from the date of your Separation from Service with the Company, (ii) the date of your death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation.  Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred.
7.Employment Policies/Confidentiality Obligations.  As a condition of your employment, you will be expected to adhere to the general employment policies and practices of the Company, including signing and abiding by the Company’s standard form of Confidential Information and Inventions Assignment Agreement.  
8.Indemnification and D&O Insurance.  You will receive an indemnification agreement for your service as an officer and director of the Company consistent with indemnification agreements in place with other executive officers of the Company.  As an officer and director of the Company, you will also be included in the Company’s annual Director and Officer Insurance program.  
9.At-Will Employment. Your employment with Company will be “at-will.”  This means that either you or Company may terminate your employment at any time, with or without Cause, and with or without advance notice.  
10.Arbitration.  To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration in Seattle, Washington, by JAMS, Inc. (“JAMS”) or its successor, under JAMS’ then applicable rules and procedures.  You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.  You will have the right to be represented by legal counsel at any arbitration proceeding.  The arbitrator shall:  (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator’s essential findings and conclusions on which the award is based.  The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law.  The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law.  

5

	
		
	
	Tableau Software, Inc.
837 North 34th Street, Suite 400
Seattle, Washington 98103
Phone:  (206) 633-3400
Fax:  (206) 633-3004

Nothing in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  
11.Miscellaneous.  This Agreement (together with the agreements referenced herein) is the complete and exclusive statement of all of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral.  It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized member of the Board.  This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the Company, and our respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company.  Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid, illegal or unenforceable provisions had never been contained herein.  This Agreement and the terms of your employment with the Company shall be governed in all aspects by the laws of the State of Washington.    
This offer is subject to our mutual acceptance of the terms and conditions of this Agreement, as well as customary and final background and reference checks, as well as your formal resignation from your current employer, and final board approval regarding such appointment.  This offer, if not accepted, will expire at the close of business on Monday, August 8, 2016.    

* * * * *
Rest of page intentionally left blank.

6

	
		
	
	Tableau Software, Inc.
837 North 34th Street, Suite 400
Seattle, Washington 98103
Phone:  (206) 633-3400
Fax:  (206) 633-3004

If you agree to the terms and conditions set forth herein, please sign below.  
We look forward to having you join us.  If you have any questions about this Agreement, please do not hesitate to call me.
Best regards,
TABLEAU SOFTWARE

/s/ John McAdam            
John McAdam
Lead Independent Director

Accepted and agreed:

/s/ Adam Selipsky            
Adam Selipsky

Date: 8/8/2016                          

7aveo-ex101_320.htm

 

 

	
 
	
Confidential Materials omitted and filed separately with the

Securities and Exchange Commission. Double asterisks denote omissions.
	
 
	
Exhibit 10.1

	
 
	
 
	
 

 

FIRST AMENDMENT  TO CO-DEVELOPMENT AND COLLABORATION AGREEMENT

This First Amendment (“First Amendment”) is made effective as of October 14, 2016 (“Amendment Effective Date”) and shall serve to modify that certain Co-Development and Collaboration Agreement dated April 9, 2014 (“Agreement”) by and between AVEO Pharmaceuticals, Inc. (“AVEO”) and Biodesix, Inc. (“Biodesix”). AVEO and Biodesix are sometimes referred to individually as a “Party” and collectively as the “Parties”.

Background

The Parties entered into the Agreement to govern the the co-development of Ficlatuzumab® (as defined in the Agreement).  The Parties wish to amend the Agreement to clarify some terms, allow for closing of the NSCLC POC Trial and allow for further development of Ficlatuzumab®.

NOW, THEREFORE, in consideration of the foregoing and the promises and conditions of this First Amendment, the parties agree as follows: 

	
1.
	
All capitalized terms in this First Amendment shall have the same meaning as defined in the Agreement.

 

	
2.
	
The Agreement shall be amended as follows:

 

	
 
	
A.
	
 AMENDED: Section 1.33 is hereby amended to read in its entirety as follows:

 

“1.33.  “FTE Cost”.  FTE Cost means the amount obtained by multiplying (a) as to FTEs expended from April 9, 2014 to May 31, 2015, (i) the number of FTEs by (ii) $[**], increased annually by the percentage increase in the CPI as of December 31 of the then most recently ended Calendar Year (if any) over the level of the CPI as of December 31, 2013 (e.g., the first such increase could occur on January 1, 2015 and would be based on the CPI percentage increase between December 31, 2013 and December 31, 2014) and (b) as to FTEs expended on or after June 1, 2015, (i) the number of FTEs by (ii) $[**], increased annually by the percentage increase in the CPI as of December 31 of the then most recently ended Calendar Year (if any) over the level of the CPI as of December 31, 2015 (e.g., the first such increase could occur on January 1, 2017 and would be based on the CPI percentage increase between December 31, 2015 and December 31, 2016).” 

 

	
 
	
B.
	
AMENDED:  Section 1.57 is hereby amended to read in its entirety as follows:

 

“1.57.  “Profit Sharing Phase”.  Profit Sharing Phase means all times during the Term

except for after the effective date of any Opt-Out.”

 

	
 
	
C.
	
AMENDED:  The final sentence of Section 2.1 is hereby amended to read in its entirety as follows: 

 

Confidential Information

Biodesix-AVEO Pharmaceuticals (Amd to Co-Dev and Collaboration Agmt)

(execution)

1

 

ActiveUS 159415190v.1

 

“For avoidance of doubt, notwithstanding any language to the contrary herein and subject to the exception below, neither Party shall charge the other Party, whether through Ficlatuzumab Cost of Goods or otherwise, any FTE or overhead costs for such Party’s [**] designated representatives’ participation in the JSC or such [**] designated representatives’ activites performed hereunder, except that each Party may charge the other Party for FTE Costs incurred from and after August 1, 2016 for such Party’s designated representatives for any activities (excluding participation in the JSC) directly related to the management or performance of the NSCLC POC Trial.”

 

	
 
	
D.
	
AMENDED:  The first paragraph of Section 9.4(b) is hereby amended to read in its entirety as follows:

 

“(b)Enforcement of  Patent  Rights.  Each Party shall have  the  sole right,  but  not the obligation,  to take action to obtain  a discontinuance  of infringement  or misappropriation  or bring suit against a Third Party infringer or misappropriator of any of Patent Rights or Know­ How solely owned by such Party; provided, however, that if either Party decides not to take such action or bring suit against a Third Party infringer or misappropriator of any Patents Rights or Know-How solely owned by such Party pursuant to Section 9.l (b), and such infringement or misappropriation is competitive as to  Ficlatuzumab  or  VeriStrat  in  connection  with Ficlatuzumab, then, subject to the terms of the AVEO Third  Party Agreements,  the other Party  shall have the option to take such action or bring such suit with respect to the Patent Rights or Know-How, and each Party agrees that it may be named as a party as may be necessary to enable the other Party to bring such action or suit.”

 

	
 
	
E.
	
 AMENDED:  The last sentence of Section 12.4 shall be amended to read as follows:

 

“By no later than date of first sale of Ficlatuzumab in conjunction with the use of VeriStrat or VeriStrat Labels, each Party agrees that it shall secure and maintain in full force and effect  the  Commercial  Insurance and Product Liability Insurance, each in the amount of at least $[**] per occurrence.”

 

	
 
	
F.
	
ADDITION/AMENDED: New Section 3.5(d) shall be added and read as follows:

 

“(d)Development Costs Incurred in Connection with the Conduct of the NSCLC POC Trial:

 

	
 
	
(i)
	
Notwithstanding Section 3.5(a), all Development Costs incurred by the Parties in connection with the conduct of the NSCLC POC Trial from and after August 1, 2016 shall be deemed to constitute Additional Development Costs and shall be borne by the Parties as set forth in Section 3.5(b)(i) as if such incurred amounts were in excess of the Cap.  For the avoidance of doubt, (A) once Biodesix satisfies its payment obligation under clause (d)(iii) below, Biodesix’s reimbursement obligation under Section 3.5(a) for all Development Costs incurred in connection with the NSCLC POC Trial up to the Cap shall be deemed fully satisfied, (B) all Development Costs incurred in connection with the NSCLC POC Trial from and after August 1, 2016 shall be deemed to be approved Development Costs constituting Additional Development Costs, which the Parties shall bear as set forth in Section 3.5(b)(i) as if such incurred amounts were in excess of the Cap, and (C) nothing in this clause (d)(i) modifies the Parties’ obligations to share in Additional Development Costs under Sections 3.5(b)(ii) and 3.5(b)(iii). 

 

Confidential Information

Biodesix-AVEO Pharmaceuticals (Amd to Co-Dev and Collaboration Agmt)

(execution)

2

 

ActiveUS 159415190v.1

 

	
 
	
(ii)
	
In consideration of AVEO’s agreement to bear 50% of the Development Costs incurred by the Parties in connection with the conduct of the NSCLC POC Trial from and after August 1, 2016 as set forth in the first sentence of clause (d)(i) above (the “AVEO-Assumed Additional Development Cost Obligation”), AVEO shall be entitled to an increase in its share of License Income pursuant to Section 4.3 and/or an increase in its share of profits pursuant to the Commercialization Agreement and/or an increase in its Opt-Out Royalty pursuant to the Commercialization Agreement and/or a decrease in Biodesix’s Opt-Out Royalty pursuant to the Commercialization Agreement, equal in aggregate to [**] times ([**]x) the AVEO-Assumed Additional Development Cost Obligation.  Such amounts shall be paid to AVEO by reducing the percentage of License Income payable by AVEO to Biodesix under Section 4.3(a) and/or Section 4.3(b) and/or by increasing the percentage of License Income payable by Biodesix to AVEO under Section 4.3(c) and/or by increasing AVEO’s share of profits pursuant to the Commercialization Agreement and/or by increasing AVEO’s Opt-Out Royalty pursuant to the Commercialization Agreement and/or by decreasing Biodesix’s Opt-Out Royalty pursuant to the Commercialization Agreement, until such time as [**] times ([**]x) the AVEO-Assumed Additional Development Cost Obligation has been paid to AVEO through such payment modifications.  Following such time as an aggregate of [**] times ([**]x) the AVEO-Assumed Additional Development Cost Obligation has been paid to AVEO through such payment modifications, the payments under Section 4.3 and/or under the Commercialization Agreement shall resume without such modifications.  For the avoidance of doubt, Biodesix shall not have any obligation to repay to AVEO the AVEO-Assumed Additional Development Cost Obligation beyond the payment modifications described above. 

 

	
 
	
(iii)
	
Within [**] days after the Amendment Effective Date, Biodesix shall pay to AVEO an amount equal to all Development Costs incurred by the Parties (and not previously paid or reimbursed by Biodesix) in connection with the conduct of the NSCLC POC Trial prior to August 1, 2016, which the Parties currently estimate were approximately [**] U.S. dollars ($[**]) (which estimate will likely change when the Parties finalize their accounting of such Development Costs during the approximately [**] following the Amendment Effective Date, in part because certain amounts payable to [**] were not confirmed as of the Amendment Effective Date), in satisfaction of Biodesix’s previously unpaid obligations under Section 3.5(a) with respect to Development Costs incurred by the Parties in connection with the conduct of the NSCLC POC Trial prior to August 1, 2016.”

 

	
3.
	
This First Amendment, together with the Agreement, constitute the entire agreement between the Parties with respect to the subject matter contained therein, and together supersede and replace any and all prior and contemporaneous understandings, arrangements and agreements, whether oral or written, with respect to such subject matter. 

 

	
4.
	
Except as provided hereinabove, the Parties hereby confirm and ratify that all terms and conditions of the Agreement, as heretofore amended, are in full force and effect and shall continue to apply, as amended by this First Amendment. 

	
5.
	
This First Amendment may be executed in two or more counterparts, each of which shall be deemed to be an original and all of which taken together shall be deemed to constitute the First Amendment when a duly authorized representative of each Party has signed a counterpart. Each Party agrees that the delivery of the First Amendment by facsimile or electronic transmission shall have the same force 

Confidential Information

Biodesix-AVEO Pharmaceuticals (Amd to Co-Dev and Collaboration Agmt)

(execution)

3

 

ActiveUS 159415190v.1

 

		
and effect as delivery of original signatures and that each Party may use such facsimile or electronic signatures as evidence of the execution and delivery of the First Amendment by all Parties to the same extent that an original signature could be used. 

IN WITNESS WHEREOF, the Parties have caused this First Amendment to be executed in multiple counterparts by their duly authorized representatives as of the Amendment Effective Date.

	
AVEO Pharmaceuticals, Inc.
	
 
	
 
	
Biodesix, Inc.

	
 
	
 
	
 
	
 

	
By:
	
/s/ Michael Bailey
	
 
	
 
	
By:
	
/s/ David Brunel

	
Name:
	
Michael Bailey
	
 
	
 
	
Name:
	
David Brunel

	
Title:
	
CEO & President
	
 
	
 
	
Title:
	
Chief Executive Officer

 

Confidential Information

Biodesix-AVEO Pharmaceuticals (Amd to Co-Dev and Collaboration Agmt)

(execution)

4

 

ActiveUS 159415190v.1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00263-of-00352.parquet"}]]